



Correction to: Polatuzumab Vedotin: First Global Approval

Emma D. Deeks¹

Published online: 15 October 2019
© Springer Nature 2019

Correction to: Drugs (2019) 79:1467–1475
<https://doi.org/10.1007/s40265-019-01175-0>

The article Polatuzumab Vedotin: First Global Approval, written by Emma D. Deeks, was originally published Online First without Open Access. After publication in volume 79, issue 13, pages 1467–1475 Roche/GCC requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Roche/GCC. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40265-019-01175-0>.

✉ Emma D. Deeks
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay,
0754 Auckland, New Zealand